LinkGevity is at the forefront of longevity science, focusing on the biological triggers of aging through its innovative Blueprint Theory. The company is pioneering a new class of drugs known as Anti-Necrotics™, which are designed to inhibit necrosis—the uncontrolled death of cells, tissues, and organs. This process is linked to accelerated aging and poses significant challenges in various fields, including chronic disease treatment, tissue engineering, and organ preservation. LinkGevity's Anti-Necrotics™ have demonstrated the ability to block necrosis by an unprecedented 90%, showcasing their potential to revolutionize medical approaches in these areas.

The company's pipeline includes both clinical and non-clinical applications of Anti-Necrotics™, targeting conditions such as Acute Kidney Injury and addressing challenges in cell culture and tissue engineering. By leveraging their proprietary Blueprint Maps, LinkGevity is identifying novel therapeutic targets and advancing exploratory programs in areas like oncology and inflammatory bowel disease. Their innovations promise to enhance the viability of primary cells, improve organ preservation, and ultimately contribute to the development of lab-grown tissues and organs, addressing critical issues such as organ shortages and the need for effective treatments in various medical fields.

United Kingdom

Based at the Babraham Research Campus in Cambridge, LinkGevity is a pioneering drug discovery company founded on ground-breaking research in longevity science. 

Our goal is to change the paradigm of ageing, paving the way for people to live healthier lives for longer.

LinkGevity

Company Details